Founded in 2014, Edinburgh Molecular Imaging (EM Imaging) is a clinical phase biotechnology company focused on enabling image guided therapy. The company’s molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue.  The focus of EM Imaging is the discovery and development of small molecules and peptides that, when conjugated with fluorescent dyes, target and specifically cancerous cells and other diseased tissue. This illumination will provide the clinician with a clearer view and decision-making tool to benefit the patient.